Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CEOP vs R-CHOP in DLBCL and Follicular Lymphoma Grade 3B
NCT01852435Phase 3Unknown
- Sponsor
- Ruijin Hospital
- Start
- May 2013
- Primary completion
- Dec 2017
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of epirubicin in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
epirubicin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01852435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01852435.